![Challenges of developing anti-drug antibody & concentration (PK or PD) assays for liposomal transgene enzymes on an automated immunoassay platform Challenges of developing anti-drug antibody & concentration (PK or PD) assays for liposomal transgene enzymes on an automated immunoassay platform](https://cdn.insights.bio/uploads/Figure/CC_GYPT_301WT_Figure1.png)
Challenges of developing anti-drug antibody & concentration (PK or PD) assays for liposomal transgene enzymes on an automated immunoassay platform
![On Demand Webinar - Discovery of High-Quality Anti-Idiotypic mAbs (Anti-Id) for Development of Critical PK/ADA Assay Reagents On Demand Webinar - Discovery of High-Quality Anti-Idiotypic mAbs (Anti-Id) for Development of Critical PK/ADA Assay Reagents](https://www.abveris.com/hs-fs/hubfs/custom-video-thumbnails/Screening%20Strategy%20for%20Anti-Idiotypic%20mAb%20(Anti-Id)%20as%20Critical%20PKADA%20Assay%20Reagents.png?width=331&name=Screening%20Strategy%20for%20Anti-Idiotypic%20mAb%20(Anti-Id)%20as%20Critical%20PKADA%20Assay%20Reagents.png)
On Demand Webinar - Discovery of High-Quality Anti-Idiotypic mAbs (Anti-Id) for Development of Critical PK/ADA Assay Reagents
![Choose the development strategy of anti-idiotypic antibody to seize the advantage of PK/ADA assay - ACROBiosystems Choose the development strategy of anti-idiotypic antibody to seize the advantage of PK/ADA assay - ACROBiosystems](https://www.acrobiosystems.com/images/upload/20220422/s3.jpg)
Choose the development strategy of anti-idiotypic antibody to seize the advantage of PK/ADA assay - ACROBiosystems
![Joint analysis of PK and immunogenicity outcomes using factorization model − a powerful approach for PK similarity study | BMC Medical Research Methodology | Full Text Joint analysis of PK and immunogenicity outcomes using factorization model − a powerful approach for PK similarity study | BMC Medical Research Methodology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12874-022-01742-2/MediaObjects/12874_2022_1742_Fig3_HTML.png)
Joint analysis of PK and immunogenicity outcomes using factorization model − a powerful approach for PK similarity study | BMC Medical Research Methodology | Full Text
![Joint analysis of PK and immunogenicity outcomes using factorization model − a powerful approach for PK similarity study | BMC Medical Research Methodology | Full Text Joint analysis of PK and immunogenicity outcomes using factorization model − a powerful approach for PK similarity study | BMC Medical Research Methodology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12874-022-01742-2/MediaObjects/12874_2022_1742_Fig5_HTML.png)
Joint analysis of PK and immunogenicity outcomes using factorization model − a powerful approach for PK similarity study | BMC Medical Research Methodology | Full Text
![A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testing - Liao - 2020 - British Journal of Clinical A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testing - Liao - 2020 - British Journal of Clinical](https://bpspubs.onlinelibrary.wiley.com/cms/asset/80303ddd-1980-43b0-b2d0-6856099b5c53/bcp14312-fig-0002-m.jpg)
A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testing - Liao - 2020 - British Journal of Clinical
![A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. - Abstract - Europe PMC A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. - Abstract - Europe PMC](https://europepmc.org/articles/PMC4012055/bin/12248_2014_9582_Sch1_HTML.jpg)
A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. - Abstract - Europe PMC
![Choose the development strategy of anti-idiotypic antibody to seize the advantage of PK/ADA assay - ACROBiosystems Choose the development strategy of anti-idiotypic antibody to seize the advantage of PK/ADA assay - ACROBiosystems](https://www.acrobiosystems.com/images/upload/20220422/s2.jpg)
Choose the development strategy of anti-idiotypic antibody to seize the advantage of PK/ADA assay - ACROBiosystems
![Correlation of the results obtained by the active drug ligand-binding... | Download Scientific Diagram Correlation of the results obtained by the active drug ligand-binding... | Download Scientific Diagram](https://www.researchgate.net/publication/283049364/figure/fig2/AS:570375525810176@1512999530979/Correlation-of-the-results-obtained-by-the-active-drug-ligand-binding-assay-and.png)
Correlation of the results obtained by the active drug ligand-binding... | Download Scientific Diagram
![Heat pre-treatment can abolish anti-drug antibody interference in ligand binding pharmacokinetic assays | AAPS Open | Full Text Heat pre-treatment can abolish anti-drug antibody interference in ligand binding pharmacokinetic assays | AAPS Open | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs41120-022-00056-3/MediaObjects/41120_2022_56_Fig4_HTML.png)